Founded in 2001, Chinese Peptide Company is a leading global integrated peptide /oligonucleotide CRDMO partner which has been dedicated in this filed for more than 20 years. In 2022, CPC has invested in a new peptide API facility in U.S. and will be utilized to manufacture clinical to commercial grade peptide products for increased manufacturing capacity and will diversify CPC’s supply chain.
